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Direct neuronal reprogramming, by which a neuron is formed via direct conversion from
a somatic cell without going through a pluripotent intermediate stage, allows for the
possibility of generating patient-derived neurons. A unique feature of these so-called
induced neurons (iNs) is the potential to maintain aging and epigenetic signatures of
the donor, which is critical given that many diseases of the CNS are age related. Here,
we review the published literature on the work that has been undertaken using iNs to
model human brain disorders. Furthermore, as disease-modeling studies using this direct
neuronal reprogramming approach are becoming more widely adopted, it is important
to assess the criteria that are used to characterize the iNs, especially in relation to the
extent to which they are mature adult neurons. In particular: i) what constitutes an iN cell,
ii) which stages of conversion offer the earliest/optimal time to assess features that are
specific to neurons and/or a disorder and iii) whether generating subtype-specific iNs is
critical to the disease-related features that iNs express. Finally, we discuss the range of
potential biomedical applications that can be explored using patient-specific models of
neurological disorders with iNs, and the challenges that will need to be overcome in order
to realize these applications.
Keywords: induced neurons, direct neural reprogramming, disease modeling, neurological disorders,
neurodegenerative diseases
INTRODUCTION
Direct reprogramming of a terminally differentiated cell into another cell type was achieved for the
first time in 1987 with the conversion of fibroblasts to myoblasts (Davis et al., 1987). Following this,
however, it took more than two decades to successfully directly reprogram fibroblasts to neuronal
cells using the forced expression of the neuronal transcription factors Ascl1, Brn2, and Myt1l - a
cell product termed induced neuron (iN) (Vierbuchen et al., 2010). Since then, the field of direct
neuronal reprogramming has been applied to human cells and been expanding at a fast pace, and
studies using patient derived iNs to model neurological disorders have started to appear.
Drouin-Ouellet et al. Patient-Specific Induced Neurons for Disease Modeling
iN cells, in contrast to induced pluripotent stem cells (iPSCs),
are the result of direct reprogramming of one type of somatic cell
into another without going through a pluripotent intermediate
stage. Because of this feature, it was hypothesized that iNs would
therefore retain some of the characteristics of the starting cell,
especially related to epigenetic status and aging. Two studies
have now demonstrated that this is the case—at least to some
extent. Using a broad range of human fibroblasts from different
age donors, Mertens et al. demonstrated that iNs exhibit an
age-dependent regulation of genes associated with aging. They
found that there is an age-dependant loss of nucleocytoplasmic
compartmentalization in donor fibroblasts which was kept in
iNs but restored in iPSCs derived from aged cells. More
specifically, they further demonstrated that RanBP17, a receptor
that decreases with aging, was also decreased in an age-dependent
manner in iN cells—features that were both absent in iPSCs
(Mertens et al., 2015a). Using different approaches to assess the
age of the cell that relies on the epigenetic DNA methylation age
measurements, a method that looks at a number of genomic loci
becoming differentially methylated with age to predict the age of
the cell (in years) (Horvath, 2013), Huh et al. have also shown that
iNs retain the age of the donors at the epigenetic level. Moreover,
they show that the aging signature is maintained through their
microRNA expression profile and increased oxidative stress levels
(Huh et al., 2016).
Neurons are especially affected by aging given that they
do not regenerate in most regions of the brain, which could
underlie why themajority of neurodegenerative disorders present
clinically later in life. As a result, age is a prominent risk factor
in many of these diseases including Alzheimer’s disease (AD),
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and
Huntington’s disease (HD). Animal models of these disorders
can mimic some aspects of these human-specific diseases but
most models are toxin- or vector-based, or use mendelian forms
of these diseases as their starting point, and do not recapitulate
the appearance of disease phenotypes associated with human
aging. As such, there is a pressing need for models that faithfully
recapitulate both the sporadic and age related aspects of these
common chronic neurodegenerative disorders in human cells.
As the number of disease modeling studies using iNs being
published are starting to increase, here we review what has been
accomplished to date, and provide an outlook of what could be
achieved in the future.
Abbreviations: 5-HT, 5-hydroxytryptamine or serotonin; AD, Alzheimer’s disease;
ALS, amyotrophic lateral sclerosis; AP, action potential; APP, amyloid precursor
protein; ASCL1, Achaete-scute homolog 1; BD, bipolar disease; BDNF, brain-
derived neurotrophic factor; bFGF, basic fibroblast growth factor; BMP, bone
morphogenetic protein; BRN2 or POU3F2, POU domain, class 3, transcription
factor 2; C or CHIR, CHIR99021; cAMP, cyclic adenosine monophosphate;
CHAT, choline acetyltransferase; ciN, chemical induced neuron; CNTF, ciliary
neurotrophic factor; CNS, central nervous system; CTIP2 or BCL11B, B-Cell
CLL/Lymphoma 11B; D or DM, dorsomorphin; DARPP32, dopamine- and
cAMP-regulated neuronal phosphoprotein; DCX, doublecortin; DLX1/2, distal-
less homeobox 1/2; F, forskolin; FACS, fluorescence-activated cell sorting; FEV,
ETS Transcription Factor; FOXA2, forkhead box protein A2; FTD, frontotemporal
dementia; FUS, fused in sarcoma; G, GO6983; GALC, galactosylceramidase;
GDNF, glial cell-derived neurotrophic factor; GSK3β, glycogen synthase kinase
3 beta; HB9, homeobox gene 9; HD, Huntington’s disease; HET, heterozygous;
CAN PATIENT-DERIVED iNS PROVIDE AN
AUTHENTIC CELLULAR SYSTEM TO
ASSESS DISEASE-RELATED
PHENOTYPES?
Patient specific neurons derived from iPSCs have shown a wide
array of disease-associated phenotypes. The majority of those
studies have studied mendelian forms of neurological disorders
but some features could also be observed in sporadic forms
of diseases such as schizophrenia, bipolar disorder and ALS
(Koch et al., 2011; Burkhardt et al., 2013; Mertens et al., 2015b).
To date, at least ten neurological disorders have been modeled
using patient-derived iN cells (see Table 1) and multiple disease-
associated phenotypes has been observed, although studies
looking at disease features in lines from sporadic patients has yet
to be reported. However, while some of these features have been
uniquely seen in iN cells, other phenotypes can be detected in
the starting cell before conversion or in neurons differentiated
from patient-derived iPSCs. Given that each cellular system has
their own merits and challenges, it will be important to decipher
the benefits that iNs have for modeling neurological disorders.
In addition to a much shorter and easier reprogramming route,
the most important difference known to date between neurons
generated from iPSCs or directly from fibroblasts is the age of
the cell. It may be, though, that iPSC derived neurons will be
best suited for modeling diseases associated with developmental
processes whereas iNs will be most useful to study disorders
associated with aging.
Disease-Associated Features Unique to
Human Cells
Mouse fibroblasts, especially at the embryonic stage, are easier
to reprogram than human adult fibroblasts and the resulting
cells mature faster. For example, spontaneous action potentials
HOMO, homozygous; ICC, immunocytochemistry; iDAN, induced dopaminergic
neuron; IGF1, insulin-like growth factor 1; iMN, induced motor neuron; iN,
induced neuron; iPSc, induced pluripotent stem cell; ISL1, insulin gene enhancer;
LAMP1, lysosomal-associated membrane protein 1; LDH, lactate dehydrogenase;
LHX3, LIM/homeobox; LM, LM-22A4; LMX1a/b, LIM homeobox transcription
factor 1, alpha or beta; LRRK2, leucine-rich repeat kinase 2; MAP2, microtubule-
associated protein 2; MOI, multiplicity of infection; MYTL1, myelin transcription
factor 1-like; NBIA, neurodegeneration with brain iron accumulation; NCAM,
neural cell adhesion molecule; ND, not determined; NEUROD1 or 2, neurogenic
differentiation 1 or 2; NF200, high molecular weight neurofilament subunit;
NGN2, neurogenin-2; NLS, nuclear localization signal; NT3, neurotrophin-
3; NURR1, nuclear receptor related 1; OLIG2, oligodendrocyte transcription
factor 2; PD, Parkinson’s disease; PGK, phosphoglycerate kinase; PINK1, PTEN-
induced putative kinase 1; PKAN, pantothenate kinase-associated; PNS, peripheral
nervous system; PSA-NCAM, polysialylated-neural cell adhesion molecule;
PSD95, postsynaptic density protein 95; PSEN 1 or 2, presenilin 1 or 2; PTB,
polypyrimidine tract-binding protein; R, repsox; RA, retinoic acid; RanBP17, RAN
binding protein 17; REST, RE1-Silencing Transcription factor; RT-qPCR, real-
time quantitative reverse transcription PCR; S, SP600125; SB, SB202190; SMA,
spinal muscular atrophy; SNP, single-nucleotide polymorphism; SOX2, SRY (sex
determining region Y)-box 2; SYN, synapsin; SYT1, synaptotagmin-1; TGFβ,
transforming growth factor beta; TH, tyrosine hydroxylase; TUJ1, neuron-specific
class III beta-tubulin; Ub, ubiquitin; UNO, unoprostone; V or VPA, valproic
acid; VACHT, vesicular acetylcholine transporter; vGLUT, vesicular glutamate
transporter; VIM, vimentin; WB, western blot; Y, Y-27632.
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can be detected in iNs originating from MEFs as early as 8
days into conversion (Vierbuchen et al., 2010), whereas the
earliest time point when spontaneous action potentials could
be detected to date in human iNs is 46 days (Xu et al.,
2015), suggesting that human cells take longer to become
fully mature. Therefore, mouse embryonic fibroblasts have been
used to study the disease mechanisms in iNs in monogenic
disorders (Chanda et al., 2013). While this approach may be a
starting point through which to study the impact of a specific
mutation on disease pathogenesis, it has been reported that
some disease-related phenotypes only have a pathology in human
iNs. For example, iNs derived from ALS patients carrying a
mutation in the fused in sarcoma (FUS) protein recapitulated the
localization of the mutated protein in the cytoplasm instead of
the nucleus following stress induction, a feature that rat primary
neurons carrying the same mutation failed to express (Lim
et al., 2016b). In another study investigating iron metabolism
in neurodegeneration with brain iron accumulation (NBIA),
mitochondrial iron and energetic dysfunction were observed
in both pantothenate kinase-associated (PKAN) patient derived
fibroblasts and iNs (Santambrogio et al., 2015), whereas these
features were not seen in fly or mouse models of the disease
(Rana et al., 2010; Brunetti et al., 2012). While there are only
a limited number of such reports published to date, they do
highlight some species-specific differences and favor the use of
human-based cellular system(s) in which the disease-associated
phenotypes will be assessed, especially given these diseases are all
uniquely human.
Disease-Associated Features Present in
iNs and Absent in Parental Fibroblasts
Disease-associated features are not always unique to the neurons
and as a result, several of these phenotypes can be observed in
both iNs and fibroblasts (Santambrogio et al., 2015; Lim et al.,
2016a). However, as iNs adopt a neuronal-like morphology and
at least some functional properties of neurons, they provide an
opportunity to study diseases in the cell type primarily clinically
affected. For example, iNs derived from adult-onset Krabbe
disease had the same lysosomal storage defects as the starting
fibroblasts, but unique to the iNs was the abnormal neuronal
branching, which may be more relevant to the clinical expression
of this disorder (Lim et al., 2016a). In fact, a few studies have
now reported that disease-associated features could only be seen
in iNs. For example, Lim et al. (2016b) reported that mutant
FUS-associated pathology was observed in iNs derived from
familial ALS patients, but not transfected cells or patient-derived
fibroblasts (Lim et al., 2016b). In line with this, an independent
study in induced motor neurons (iMNs) also reported such
disease-associated phenotype (Liu et al., 2016). In another report,
Toxoplasma gondii infection of iN cells derived from patients
with childhood onset schizophrenia resulted in cyst formation
due to T. gondii differentiation in the iN soma, whereas the
infected parental fibroblasts were completely lysed by parasite
infection (Passeri et al., 2016). Given that the conversion of
the fibroblasts to iN cells allowed the formation of cysts, this
argues in favor of the specific need of the relevant neuronal cell
type to assess disease pathogenesis. Other examples illustrating
this point include a study showing that changes at the level
of pathological protein expression have also been observed,
with elevated levels of Aβ42 as well as phosphorylated Tau
in iNs derived from patients with familial AD as compared
to fibroblasts (Hu et al., 2015). Finally, the investigation of
phenotypes associated with the repeat expension r(GGGGCC)exp
in C9orf72 that leads to frontotemporal dementia (FTD) and
ALS resulted in the detection of cytoplasmic poly(GP) as well
as poly(PR) inclusions in iNs but not in fibroblasts (Su et al.,
2014).
One important caveat with most of these studies, however,
is that the iNs that have been used for disease modeling
were mostly at early stages of conversion, and thus rather
immature neurons in terms of function, marker expression and
morphology. Additionally, most studies have been performed
on a pan-neuronal or unspecified neuronal subtype rather
than on a specific subtype of neuron. When using iPSCs
for disease modeling, subtype specific disease-related features
have been reported to be important. For instance, abnormal
neuronal arborization was observed in dopaminergic neurons
bearing a Leucine-rich repeat kinase 2 (LRRK2) mutation but
not in sensory neurons differentiated from the same cell source
(Schwab and Ebert, 2015). It is thus likely that iNs of different
subtypes may express distinct disease-related phenotypes, which
will be important to study given that most of these diseases
have pathology that is region specific in the CNS/PNS. This
ability to generate subtype specific neurons has now been
achieved for many types of neurons, including dopaminergic
(Caiazzo et al., 2011; Pfisterer et al., 2011a), striatal medium
spiny (Victor et al., 2014), cholinergic (Liu et al., 2013; Zhang
et al., 2017), nociceptive (Wainger et al., 2015), spinal motor
(Son et al., 2011; Liu et al., 2016), GABAergic interneurons
and serotoninergic neurons (Xu et al., 2015; Vadodaria et al.,
2016) (see Figure 1). Furthermore, the generation of such
subtype specific iNs provides the advantage to expand the
array of functional assays that can be performed. For example,
the formation of functional neuromuscular junctions by iMN
could be evaluated in co-cultures with primary mouse skeletal
myotubes, as well as through more conventional approaches
such as electrophysiologically, a functional aspect which has been
shown to be impaired in iMNs derived from ALS patients (Liu
et al., 2016).
Ideally, investigation of disease-associated phenotypes should
be done using neuron specific subtypes and comparing subtypes
of cells that are, or are not, affected in the disease process. For
this purpose, the generation of additional subtypes of neurons as
well as the optimization of current reprogramming protocols to
produce iNs that mimic more closely the cellular phenotypes of
the diverse human neuronal subtypes is needed. This, however,
will remain challenging as long as the mechanisms behind
fate specification during direct reprogramming are not better
understood. Furthermore the production of a high yield of
subtypes specific iNs is technically very challenging given that this
often requires the delivery of a greater number of reprogramming
factors and as a result, only a small subset of cells expresses the full
set.
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FIGURE 1 | Methods for direct neuronal conversion. During direct neuronal conversion, adult human fibroblasts undergo progressive conversion into iNs. This
process is initiated by a lentiviral transduction (1) to deliver the reprogramming factors and/or the addition of chemical compounds (2, 3). Neuronal identity can be
confirmed by the expression of pan-neuronal markers (4). iN cultures can further be purified using antibiotic selection and/or cell sorting (5). Subtype specific neurons
can also be obtained by the addition of fate determinant reprogramming factors (6).
HOW TO DEFINE AN iN?
The term iN has been used to describe neurons generated
from multiple cell sources and through multiple methods.
A first important distinction should be made between
neurons differentiated from iPSCs using extrinsic factors,
neurons obtained from pluripotent stem cells through the
forced expression of programming factors or via the direct
reprogramming of somatic cells to neuronal progenitors and
further differentiated into mature neurons. Here, we define iNs
as the product of directly reprogrammed neurons starting from
somatic cells, such as a fibroblast, and avoiding a pluripotent or
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progenitor stage intermediate and we focus on iNs produced
from adult human fibroblasts due to their utility in disease
modeling.
These type of adult iNs have been generated using four main
methods: (i) by the forced expression of transcription factors
(Caiazzo et al., 2011; Pfisterer et al., 2011b; Iovino et al., 2014;
Mertens et al., 2015a; Passeri et al., 2015; Siegert et al., 2015; Liu
et al., 2016), (ii) by knocking down of the RNA-binding proteins
PTB/nPTB (Xue et al., 2016) or p16-p19 (Sun et al., 2014),
(iii) by the forced expression of neuronal specific microRNAs
(Victor et al., 2014; Richner et al., 2015; Huh et al., 2016), (iv)
by chemically manipulating pathways involved in neuronal fate
and functions (Hu et al., 2015) or by a different combination
of these strategies (Ambasudhan et al., 2011; Liu et al., 2013;
Hsu et al., 2014; Wang et al., 2014; Xu et al., 2015; Drouin-
Ouellet et al., 2017) (Figure 1). Each of these methods has been
proven effective in generating functional neurons in which it is
possible to evoke action potentials as well as observe spontaneous
synaptic activity within a timeframe ranging from 4 to 12 weeks
when co-cultured with astrocytes or primary cortical neurons
or after transplantation (Hu et al., 2015; Huh et al., 2016; Liu
et al., 2016; Xue et al., 2016; Drouin-Ouellet et al., 2017), and
even spontaneous action potentials in some cases (Mertens et al.,
2015a). The resulting iNs have also been shown to express
mature neuronal markers including MAP2, TAU, and NEUN
with complex neuronal morphology.
To date, the predominant method by which to isolate/identify
the iN population to assess disease relevant phenotypes in patient
derived iNs, has involved either an antibiotic selection to remove
cells that are not expressing the reprogramming construct(s)
(Liu et al., 2014; Su et al., 2014; Bavamian et al., 2015; Lim
et al., 2016a) or based on the expression of neuronal markers
such as TUJ1 (βIII-Tubulin) (Iovino et al., 2014; Liu et al.,
2014; Fiesel et al., 2015; Lim et al., 2016a,b; Puschmann et al.,
2017). However, direct neuronal reprogramming studies that
have used antibiotic selection to purify the neuronal culture
have consistently reported that a significant percentage of cells
do not convert even though the reprogramming constructs
are expressed (Victor et al., 2014; Mertens et al., 2015a; Huh
et al., 2016; Liu et al., 2016; Xue et al., 2016), which presents
the need to identify the iN population even after antibiotic
selection. Furthermore, using a method that combines the forced
expression of Ascl1 and Brn2 with the knockdown of the
neuronal repressor complex REST, we show that although an
important proportion of cells expressing stronger levels of TUJ1
can be observed very early on, only a few MAP2+ or TAU+
cells are detectable around day 18 and this number increases at
day 25 (Figure 2). Notably, a striking and progressive change in
cell morphology toward a more mature neuronal appearance is
observed over time—e.g., a decrease of the size of the nucleus
and cell body, thinning and elongation of the processes and
increase in the number of branches. As expected, some markers
of fibroblasts and non-mature neurons such as Vimentin can
be co-expressed with mature neuronal markers in iNs even at
later time points (Figure 3A), whereas the marker TE7, which is
fibroblast-specific, is not co-expressed in TUJ1+ cells as early as
day 10 (Figure 3B). Indeed Xue et al. (2016) have reported that
TUJ1 is expressed as early as 3 h following shPTB and plateaus at
1 day post transduction - at a time when a fibroblast marker such
as fibronectin is still strongly expressed and when the transduced
cells do not exhibit a full neuronal morphology (Xue et al., 2016).
These authors have also shown that knocking down PTB is not
sufficient to induce the expression of mature neuronal markers
such as MAP2 and NEUN in adult human fibroblasts but that the
full maturation of iNs requires sequential nPTB knockdown. As
a result, the neuronal identity of iNs used in disease modeling
studies that have both knocked down PTB and used TUJ1 as
a neuronal marker or only antibiotic selection to obtain the iN
population, has not been confirmed.
These challenges with iN reprogramming can lead to potential
bias when assessing neuron-specific phenotypes associated with
different disorders as cells not fully converted or not fully mature
may not be an ideal system for modeling of diseases in which the
primary cell population affected are neurons. As such, we suggest
that disease modeling studies should use:
1. One of the methods that have been proven to generate mature
neurons in adult human fibroblasts (Hu et al., 2015; Mertens
et al., 2015a; Richner et al., 2015; Xue et al., 2016; Drouin-
Ouellet et al., 2017), or new methods where the neuronal
identity and function is well documented.
2. The expression of at least one of the following markers
(MAP2, TAU, and/or NEUN) to identify the neurons and
3. Morphological criteria for neuronal identification and
4. Conversion protocols with maturation times in vitro of at least
4 weeks.
FUTURE OUTLOOK
Although the field of modeling neurological disorders with iN
cells is still in its early stages, the results reported thus far support
the need for further development of the iN technology, as it
has already been shown to be useful in studying some neuronal
specific age related human diseases. Up until very recently,
the methods used to obtain iNs have been rather inefficient
when applied to adult human fibroblasts, which has greatly
hampered their utility for disease modeling. To circumvent this
issue, we have developed a simple single-step and single-vector
based approach that can generate very high yields of iNs from
patients with neurodegenerative disorders independent of the
passage number of the fibroblasts (Drouin-Ouellet et al., 2017).
This new approach results in cells that fulfill the above criteria
for iN cell suitable for disease modeling as outlined above
(expression of mature neuronal markers, neuronal morphology,
more than 4 weeks maturation in vitro) and overtime the cells
develop functional properties of neurons including post-synaptic
currents and the ability to fire action potentials. The simplicity
and high efficiency of the method should facilitate the application
of direct neuronal reprogramming for disease modeling
studies.
The use of iNs is advantageous in terms of allowing studies
of large cohort of patients and controls including patients with
sporadic diseases within shorter time, with relatively little work
and cost compared to iPSC-based modeling. Another advantage
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FIGURE 2 | Timeline of neuronal marker expression during reprogramming. Representative images of TUJ1 and MAP2 double immunostaining counterstained with
DAPI (in blue) showing low levels of TUJ1 in dermal fibroblasts (in green), followed by intensification of expression at day 10, which is sustained until day 25
post-transduction with the U6.shREST.PGK.BRN2.PGK.ASCL1.WPRE construct. MAP2 expression (in red) is detectable in the nucleus at day 10 and is incrementally
expressed in the processes from day 18 to 25. Scale bar = 25µm.
of iN cells is that they maintain, at least partially, the aging
signature of the cell, and are therefore more likely to provide
insights into the molecular mechanisms underlying the age-
dependent pathogenesis of some neurological disorders, as well
as the pathological basis of their clinical heterogeneity.
Another potential advantage of iNs is that they do not
rely on clonal selection and while this could result in a
higher heterogeneity of the final neuronal population, the end
product as a whole is more likely to be biologically relevant
than a few selected iPSC clones. Furthermore, as methods for
producing glial cells by direct reprogramming are emerging
(Caiazzo et al., 2015; Tian et al., 2016), we can expect a greater
sophistication of the induced cellular systems and with this, a
more comprehensive assessment of specific non-cell autonomous
interactions involving multiple neural cell types during disease
processes on a patient-specific basis.
Once models for a diverse range of neurological disorders
using iNs have been well established, we anticipate that there
will be an expansion of the field toward early and differential
diagnostics, drug target validation as well as drug screening
assays. However, for this to become a reality, a number
of challenges need to be overcome. For instance, careful
characterization of the cell product should be carried out in
terms of neuronal phenotypes as well as subtype authenticity to
mimic as close as possible the types of neurons that are found
and affected in the human brain. In that respect, more molecular
studies at the single cell level are warranted to better understand
the relationship between the reprogramming and the endogenous
factors, as well as the target level of expression needed to perfect
the end cell product. In support of this, novel reprogramming
strategies which ensure that the full set of factors are expressed
in each starting cell, and which provide a better control of
their expression level will improve the yield of the target iN
subpopulations. Finally, further insights into the mechanisms of
direct reprogramming will undoubtedly help shed light on how
best to bring iN technology to the point where it becomes a
routine tool, as well as possible therapeutic approach in its own
right.
METHODS
An adult dermal fibroblast line derived from a skin biopsy from
a neurologically healthy 71-year-old male was obtained from the
Parkinson’s Disease Research clinic at the John van Geest Centre
for Brain Repair (Cambridge, UK) and used under local ethical
approval (REC 09/H0311/88). Written informed consent was
obtained from the participant, and the experiments conformed to
the principles set out in theWMADeclaration ofHelsinki and the
Department of Health and Human Services Belmont Report. For
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FIGURE 3 | Timeline of fibroblast marker expression during reprogramming. (A) Double immunofluorescent staining of the fibroblast and neuronal progenitor marker
Vimentin (VIM; in green) and the neuronal marker TAU (in red) counterstained with DAPI (in blue) showing Vimentin expression in dermal fibroblasts as well as in a
subpopulation of cells that are not expressing TAU at day 18 and 25 post-transduction. The majority of TAU expressing cells do not express VIM except for a few
cells, which are double TAU/VIM+ (white arrowheads). (B) TUJ1 (cyan), MAP2 (red) and TE7 (green) triple immunostaining counterstained with DAPI (in blue) showing
expression of the fibroblast marker TE7 in fibroblasts before transduction, whereas TUJ1+ and MAP2+ cells are negative for TE7, which is only detectable
extracellularly at later time points during conversion. Scale bar in A = 25µm, B =100µm.
details on the skin biopsy sampling and the fibroblast cultures,
refer to Drouin-Ouellet et al. (2017).
Neuronal reprogramming was done as described before
(Drouin-Ouellet et al., 2017) using a single third-generation
lentiviral vector expressing a combination of Ascl1 and Brn2
with short hairpin RNA (shRNA) targeting REST. It was
generated with a non-regulated ubiquitous phosphoglycerate
kinase (PGK) promoter produced as previously described
(Zufferey et al., 1997) and titrated by quantitative PCR (qPCR)
analysis (Georgievska et al., 2004). Transduction was performed
at a multiplicity of infection (MOI) of 20. The virus titer was
1.93E+ 09.
Immunocytochemistry was performed at day 0, 10, 18
and 25 as previously described (Drouin-Ouellet et al., 2017).
The following primary antibodies were used in the blocking
solution overnight at 4◦C: chicken anti-MAP2 (1:15,000; Abcam,
ab5392); mouse anti-TUJ1 (1:1,000; Promega, G7121); rabbit
anti-TUJ1 (1:1,000; BioLegend, 801201); chicken anti-VIM
(1:5,000; Millipore, AB5733); mouse anti-TAU clone HT7
(1:500, Thermo Scientific, MN1000); mouse anti-TE7 (1:100,
Millipore, CBL271). On the second day, after washing twice with
PBS, Cyanine-conjugated secondary antibodies (1:200; Jackson
ImmunoResearch Laboratories) were added and counterstained
with DAPI (1:1,000; Sigma-Aldrich). Images were captured from
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a PBS-filled well at 20X using an inverted microscope (Leica,
DFC360 FX-DMI 6000B).
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